Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment Modalities for T1N0 Esophageal Cancers: A Comparative Analysis of Local Therapy Versus Surgical Resection  Mark F. Berry, MD, Josiane Zeyer-Brunner,

Published bySiska Makmur Modified over 5 years ago

Similar presentations

Presentation on theme: "Treatment Modalities for T1N0 Esophageal Cancers: A Comparative Analysis of Local Therapy Versus Surgical Resection  Mark F. Berry, MD, Josiane Zeyer-Brunner,"— Presentation transcript:

1 Treatment Modalities for T1N0 Esophageal Cancers: A Comparative Analysis of Local Therapy Versus Surgical Resection  Mark F. Berry, MD, Josiane Zeyer-Brunner, MMed, MLaw, Anthony W. Castleberry, MD, MMCi, Jeremiah T. Martin, MD, Beat Gloor, MD, Ricardo Pietrobon, MD, PhD, Thomas A. D'Amico, MD, Mathias Worni, MD, MHS  Journal of Thoracic Oncology  Volume 8, Issue 6, Pages (June 2013) DOI: /JTO.0b013e bf1 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Change of use of esophagectomy and local therapy from 1998 to Straight line: esophagectomy. Discontinuous line: local therapy. Multivariable adjusted p for trend < (odds ratio per year: 1.18, 95% confidence interval: 1.11–1.25). Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e bf1) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Five-year CSS and OS comparing esophagectomy and local therapy. Number of patients at risk at time 0 (esophagectomy: n = 1204; local therapy: n = 254). Log-rank test for CSS: p = 0.10, and for OS: p = CSS, cancer-spefic survival; OS, overall survival. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e bf1) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 A, CSS and OS comparing esophagectomy and local therapy in T1a tumor subgroups. Number of patients at risk at time 0 (esophagectomy: n = 302; local therapy: n = 119). Log-rank test for CSS: p = 0.93, and for OS: p = B, CSS and OS comparing esophagectomy and local therapy in T1b tumor subgroups. Number of patients at risk at time 0 (esophagectomy: n = 296; local therapy: n = 27). Log-rank test for CSS: p = 0.07, and for OS: p = CSS, cancer-specific survival; OS, overall survival. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e bf1) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Treatment Modalities for T1N0 Esophageal Cancers: A Comparative Analysis of Local Therapy Versus Surgical Resection  Mark F. Berry, MD, Josiane Zeyer-Brunner,"

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution  Linda W. Martin, MD, Arlene.

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution  Linda W. Martin, MD, Arlene.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
The Relationship Between Volume or Surgeon Specialty and Outcome in the Surgical Treatment of Lung Cancer: A Systematic Review and Meta-Analysis  Erik.

The Relationship Between Volume or Surgeon Specialty and Outcome in the Surgical Treatment of Lung Cancer: A Systematic Review and Meta-Analysis  Erik.
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma  Clive J. Kelty, MB, ChB, PhD, FRCSEd,

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma  Clive J. Kelty, MB, ChB, PhD, FRCSEd,
Mark F. Berry, MD, Thomas A. Sporn, MD, Joseph O. Moore, MD, Thomas A

Mark F. Berry, MD, Thomas A. Sporn, MD, Joseph O. Moore, MD, Thomas A
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,
The Relationship Between Volume or Surgeon Specialty and Outcome in the Surgical Treatment of Lung Cancer: A Systematic Review and Meta-Analysis  Erik.

The Relationship Between Volume or Surgeon Specialty and Outcome in the Surgical Treatment of Lung Cancer: A Systematic Review and Meta-Analysis  Erik.
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H

Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,
Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller  Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller  Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Similar presentations

Ads by Google